Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Orexin receptor antagonists: a review of promising compounds patented since 2006
Paul J. Coleman, John J. Renger
Expert Opinion on Therapeutic Patents (2010) Vol. 20, Iss. 3, pp. 307-324
Closed Access | Times Cited: 60

Showing 26-50 of 60 citing articles:

Synthesis and Evaluation of Novel Radioligands for Positron Emission Tomography Imaging of the Orexin-2 Receptor
Norihito Oi, Michiyuki Suzuki, Taro Terauchi, et al.
Journal of Medicinal Chemistry (2013) Vol. 56, Iss. 16, pp. 6371-6385
Closed Access | Times Cited: 26
Effects of changes in energy homeostasis and exposure of noxious insults on the expression of orexin (hypocretin) and its receptors in the brain
Rita Machaalani, Nicholas J. Hunt, Karen A. Waters
Brain Research (2013) Vol. 1526, pp. 102-122
Closed Access | Times Cited: 24
Discovery of 2,5-diarylnicotinamides as selective orexin-2 receptor antagonists (2-SORAs)
Swati P. Mercer, Anthony J. Roecker, Susan L. Garson, et al.
Bioorganic & Medicinal Chemistry Letters (2013) Vol. 23, Iss. 24, pp. 6620-6624
Closed Access | Times Cited: 24
Entry‐into‐humans study with ACT‐462206, a novel dual orexin receptor antagonist, comparing its pharmacodynamics with almorexant
Matthias Hoch, Helene C. van Gorsel, Joop van Gerven, et al.
The Journal of Clinical Pharmacology (2014) Vol. 54, Iss. 9, pp. 979-986
Closed Access | Times Cited: 23
Orexin receptor agonist Yan 7874 is a weak agonist of orexin/hypocretin receptors and shows orexin receptor-independent cytotoxicity
Ainoleena Turku, Maiju K. Rinne, Gustav Boije af Gennäs, et al.
PLoS ONE (2017) Vol. 12, Iss. 6, pp. e0178526-e0178526
Open Access | Times Cited: 22
Disubstituted piperidines as potent orexin (hypocretin) receptor antagonists
Rong Jiang, Xinyi Song, Purva Bali, et al.
Bioorganic & Medicinal Chemistry Letters (2012) Vol. 22, Iss. 12, pp. 3890-3894
Open Access | Times Cited: 22
Design, synthesis, and structure–activity relationships of a series of novel N-aryl-2-phenylcyclopropanecarboxamide that are potent and orally active orexin receptor antagonists
Yu Yoshida, Taro Terauchi, Yoshimitsu Naoe, et al.
Bioorganic & Medicinal Chemistry (2014) Vol. 22, Iss. 21, pp. 6071-6088
Closed Access | Times Cited: 20
G Proteins, p60TRP, and Neurodegenerative Diseases
Klaus Heese
Molecular Neurobiology (2013) Vol. 47, Iss. 3, pp. 1103-1111
Closed Access | Times Cited: 19
Discovery of HTL6641, a dual orexin receptor antagonist with differentiated pharmacodynamic properties
J.A. Christopher, Sarah J. Aves, Jason Brown, et al.
MedChemComm (2015) Vol. 6, Iss. 5, pp. 947-955
Closed Access | Times Cited: 17
Discovery of substituted lactams as novel dual orexin receptor antagonists. Synthesis, preliminary structure–activity relationship studies and efforts towards improved metabolic stability and pharmacokinetic properties. Part 1
Thierry Sifferlen, Amandine Boller, Audrey Chardonneau, et al.
Bioorganic & Medicinal Chemistry Letters (2014) Vol. 24, Iss. 4, pp. 1201-1208
Closed Access | Times Cited: 16
Discovery of spiropiperidine-based potent and selective Orexin-2 receptor antagonists
Tatsuhiko Fujimoto, Yoshihide Tomata, Jun Kunitomo, et al.
Bioorganic & Medicinal Chemistry Letters (2011) Vol. 21, Iss. 21, pp. 6409-6413
Closed Access | Times Cited: 16
Discovery of 1 H -pyrazolo[3,4- b ]pyridines as potent dual orexin receptor antagonists (DORAs)
Dirk Behnke, Simona Cotesta, Samuel Hintermann, et al.
Bioorganic & Medicinal Chemistry Letters (2015) Vol. 25, Iss. 23, pp. 5555-5560
Closed Access | Times Cited: 15
The distribution of hypocretin/orexin receptor mRNA in the mouse and human brain
Sanjida Mir, Ryan J. Keenan, Romke Bron, et al.
Medicine in Drug Discovery (2024) Vol. 24, pp. 100202-100202
Open Access | Times Cited: 1
Obesity Drug Update: The Lost Decade?
Fayi Yao, Robert G. MacKenzie
Pharmaceuticals (2010) Vol. 3, Iss. 12, pp. 3494-3521
Open Access | Times Cited: 15
Structure–activity relationship studies and sleep-promoting activity of novel 1-chloro-5,6,7,8-tetrahydroimidazo[1,5-a]pyrazine derivatives as dual orexin receptor antagonists. Part 2
Thierry Sifferlen, Ralf Koberstein, Emmanuelle Cottreel, et al.
Bioorganic & Medicinal Chemistry Letters (2013) Vol. 23, Iss. 13, pp. 3857-3863
Closed Access | Times Cited: 13
Orexin Receptor Antagonists
J.A. Christopher
Pharmaceutical Patent Analyst (2012) Vol. 1, Iss. 3, pp. 329-346
Closed Access | Times Cited: 13
International Union of Basic and Clinical Pharmacology CXIV: Orexin Receptor Function, Nomenclature and Pharmacology
Jyrki P. Kukkonen, Laura H. Jacobson, Daniël Hoyer, et al.
Pharmacological Reviews (2024), pp. PHARMREV-000953
Open Access | Times Cited: 1
Synthesis, structure–activity relationship studies, and identification of novel 5,6,7,8-tetrahydroimidazo[1,5-a]pyrazine derivatives as dual orexin receptor antagonists. Part 1
Thierry Sifferlen, Ralf Koberstein, Emmanuelle Cottreel, et al.
Bioorganic & Medicinal Chemistry Letters (2013) Vol. 23, Iss. 7, pp. 2212-2216
Closed Access | Times Cited: 11
Mechanistic Insights into Mode of Action of a Potent Natural Antagonist of Orexin Receptor-1 by Means of High Throughput Screening and Molecular Dynamics Simulations
Jaspreet Dhanjal, Sonam Grover, Prateek Paruthi, et al.
Combinatorial Chemistry & High Throughput Screening (2014) Vol. 17, Iss. 2, pp. 124-131
Closed Access | Times Cited: 9
Targeting the orexinergic system: Mainly but not only for sleep-wakefulness therapies
Abdelaziz Ghanemi, Xintian Hu
Alexandria Journal of Medicine (2014) Vol. 51, Iss. 4, pp. 279-286
Open Access | Times Cited: 8
Investigation of New Orexin 2 Receptor Modulators Using In Silico and In Vitro Methods
Jana Janočková, Rafael Doležal, Eugenie Nepovimová, et al.
Molecules (2018) Vol. 23, Iss. 11, pp. 2926-2926
Open Access | Times Cited: 8
G‐Protein–Coupled Receptor Deorphanizations
Yumiko Saito, Olivier Civelli
International review of neurobiology (2005), pp. 179-209
Closed Access | Times Cited: 10
2-Methyl-3-furanyl-4H-1,2,4-triazol-3-ylthioamides: A new class of selective orexin 2 antagonists
Fabrizio Micheli, Marinella Antolini, Romano Di Fabio, et al.
Bioorganic & Medicinal Chemistry Letters (2010) Vol. 20, Iss. 22, pp. 6405-6407
Closed Access | Times Cited: 6
Absence of Pharmacokinetic and Pharmacodynamic Interactions between Almorexant and Warfarin in Healthy Subjects
Jasper Dingemanse, Petra Hoever
Drugs in R&D (2013) Vol. 13, Iss. 2, pp. 145-151
Open Access | Times Cited: 5
Treatment and prevention of various therapeutic conditions using OX receptor antagonistic activity (WO2012081692)
J.A. Christopher, Miles Congreve
Expert Opinion on Therapeutic Patents (2013) Vol. 23, Iss. 2, pp. 273-277
Closed Access | Times Cited: 3

Scroll to top